CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Innova Captab Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Innova Captab Ltd
Sco-301, 2nd floor,Sector-9,
Phone: +91 1724194500p:+91 1724194500 PANCHKULA, 134109  India Ticker: INNOVACAPINNOVACAP
Business Summary
Innova Captab Ltd is an integrated pharmaceutical company. The Company is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has presence across the pharmaceuticals value chain, including research and development, manufacturing, drug distribution and marketing and exports. Its business includes CDMO business, domestic branded generics business, and international branded generic product business. Its CDMO business provides research, product development and manufacturing services. Its branded generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under its own brand names through online and offline channels. Its generic drug products are also available online through various e-commerce pharmacy sites. It has developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer LokeshBhasin 3/30/2024 3/30/2024
Compliance Officer, Company Secretary NeeharikaShukla 5/9/2022 5/9/2022
Managing Director Vinay K.Lohariwala 46 3/3/2010 3/3/2010
7 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 57,224,929 (As of 12/29/2023)
Stock Exchange: NSE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024